Results
VUB spin-off Precirix NV enters into alliance with 3P Biopharmaceuticals
Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and 3P Biopharmaceuticals S.L.U.
Read more
VUB spin-off eTheRNA immunotherapies opens office in Hong Kong
eTheRNA immunotherapies NV, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, announced the opening of its new subsidiary, eTheRNA Asia Limited (‘eTheRNA Asia’), with offices located in the Sheung Wan area of Hong Kong. &nbs...
Read more
Gold and silver mining from Brussels urban sewage
Researchers from the VUB and ULB have succeeded in extracting gold, silver and other precious materials from the Brussels sewage water. With the SUBLIMUS project they are looking for a way to do this on a large scale. The project is coordinated by Dr.
Read more
New open access cleanroom for microfabrication of microfluidic devices in glass and silicon
MICROLAB: VUB launching a new open access cleanroom for microfabrication of microfluidic devices in glass and silicon Microfluidics is a recent multidisciplinary scientific field concerned with the study and manipulation of fluids in channels smaller than 1 mm.
Read more
Innovative VUB spin-offs in healthcare are thriving
August brought us exciting news from 3 VUB spin-offs: eTheRNA, Fertiga and Precirix . They are active in the health sector and develop life-changing innovations in fertility and for the treatment of cancer & infectious diseases. Read more
Read more
President of EC visits AI Experience Center
The VUB AI Experience Center is a high-tech test, demonstration and meeting environment where companies, technological entrepreneurs, researchers and policy makers can experiment with AI and work together to develop and produce technological solutions.
Read more
€3m for new cancer offensive
A consortium of the VUB and three Flemish companies has a budget of 3 million euros to test a new immunotherapy on patients with colon cancer. (Ex-) professor Kris Thielemans (VUB) is the scientific leader of the project.
Read more
double pass partners with FIFA
VUB spin-off Double pass specialised in sport technical and talent development management, has been chosen as the partner to roll out FIFA’s new groundbreaking Talent Development Programme.
Read more
VUB develops self-learning automatic wheelchair
A team of scientists active within the VUB AI Experience Center has now developed a new algorithm for a self-driving wheelchair that learns much faster and independently on the basis of trail and error than existing versions.
Read more
Artificial Intelligence used to detect tumors
In cancer, AI has shown great promise in characterizing tumors, suggesting appropriate treatments and predicting patient survival.
Read more